MarketInOut Stock Screener Log In | Sign Up

Arbutus Biopharma Corp

IEX • Healthcare • Biotechnology • Quote as of 10/30/2026
Arbutus Biopharma Corp stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization645.29 mln
Float153 mln
Earnings Date11/11/2026

EPS

0.79
Decent

P / E

5.33
Undervalued

Piotroski F-Score

6 / 9
Solid

1-Year Forecast

5.46
Strong upside

Relative Strength

46 / 100
Slightly lagging

Debt / Equity

0.01
Debt-free

Business Description

Arbutus Biopharma is a clinical-stage company based in Warminster, Pennsylvania, focused on developing new treatments for chronic Hepatitis B. Its two lead drug candidates work in complementary ways ? one reduces harmful viral proteins in the body, while the other helps the immune system recognize and fight the infection. The company also holds a licensing agreement with Alnylam Pharmaceuticals to use their drug delivery technology in developing its products.

Key Fundamentals

EPS0.79
P/E5.33
ROE101
RPS0.94
ROIC200
ROA90.37
Interest Cover1,940
EBITDA, mln153
EV / EBITDA4.96
EV / EBIT4.96
Revenue, mln182
EV / Revenue4.18

Quote Details

Last 4.22
Change -0.06 (-1.4%)
Open 4.28
Volume 1,877,982
Turnover 7,925,084
Average Volume 2,673,332

Financial Ratios

Pre-Tax Profit Margin84
Leverage Ratio1.06
Current Ratio81.42
Price / Book3.27
Price / Tangible Book3.27
Debt / Equity0.01
Price / Sales4.62
PEG Ratio0.24

Financial Strength

Altman Z-Score30.13
Piotroski F-Score 6 / 9
Price to Graham Number0.90
1-Year Target Price5.46
Short Ratio3.22
Short % of Float27.75

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0.24% 52 / 100   
1 Month -7.46% 27 / 100   
2 Months -4.31% 40 / 100   
6 Months -2.31% 41 / 100   
1 Year -8.66% 38 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog